Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data

Core Insights - Journey Medical Corp (NASDAQ: DERM) is recognized as one of the best-performing micro-cap stocks in 2025, with a Buy rating reaffirmed by Lake Street analyst Thomas Flaten and a price target of $13 [1]. Group 1: Clinical Trial Results - Journey Medical published positive results from a Phase 1 clinical trial for Emrosi, an FDA-approved oral medication for skin conditions, in the Journal of Drugs in Dermatology [2]. - The trial met all three primary endpoints: no significant microbiome changes in skin, no notable antibiotic resistance to minocycline, and no major rise in opportunistic organisms compared to placebo [3]. - Emrosi is well tolerated with no significant safety concerns, supporting its low-dose profile to minimize disruption to normal body flora for safe, extended use in rosacea patients [3]. Group 2: Product Development and Approval - Emrosi received FDA approval in November 2024, making it the only oral therapy approved for treating both inflammatory lesions and redness in rosacea, supported by two Phase 3 clinical trials conducted in the US and Germany [5]. - Journey Medical Corp focuses on developing and marketing prescription dermatology products, with a portfolio that includes treatments for acne, rosacea, actinic keratosis, and fungal infections [6]. Group 3: Leadership Insights - Claude Maraoui, co-founder, president, and CEO of Journey Medical, emphasized that the publication reinforces Emrosi's differentiated benefits as a low-dose option that avoids significant microbial disruption or resistance, based on consistent data across trials [4].